Telix Pharmaceuticals Files 6-K Report
Ticker: TLX · Form: 6-K · Filed: 2026-04-09T21:26:00-04:00
Sentiment: neutral
Topics: regulatory-filing, corporate-update
TL;DR
Telix Pharma dropped a 6-K filing on 4/10/26 - check it for Pixclara updates and financials.
AI Summary
On April 10, 2026, Telix Pharmaceuticals Ltd. filed a 6-K report with the SEC. The filing includes financial information and exhibits, such as a press release regarding Pixclara, a new imaging agent. The company's mailing and business address is 55 Flemington Road, North Melbourne, C3 3051.
Why It Matters
This filing provides an update on Telix Pharmaceuticals' corporate activities and financial reporting, which is important for investors tracking the company's progress and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine 6-K filing providing corporate information and is not indicative of immediate material changes.
Key Players & Entities
- Telix Pharmaceuticals Ltd (company) — Filer of the 6-K report
- Pixclara (product) — Mentioned in an exhibit to the 6-K
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign issuer required by the SEC, used to furnish information which the issuer makes or is required to make public pursuant to the laws of its home country or its home country's stock exchange, or that it otherwise makes or is required to make public.
When was this 6-K filing accepted by the SEC?
This 6-K filing was accepted by the SEC on April 9, 2026.
What is the CIK number for Telix Pharmaceuticals Ltd?
The CIK number for Telix Pharmaceuticals Ltd is 0002007191.
What is the SIC code listed for Telix Pharmaceuticals Ltd?
The SIC code listed for Telix Pharmaceuticals Ltd is 2834, which corresponds to Pharmaceutical Preparations.
What documents are included in this 6-K submission?
This 6-K submission includes the main 6-K document, an exhibit (EX-99.1), and several graphic files, along with a complete submission text file.
From the Filing
EDGAR Filing Documents for 0001628280-26-024572 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]: SEC Accession No. 0001628280-26-024572 Filing Date 2026-04-10 Accepted 2026-04-09 21:26:00 Documents 5 Period of Report 2026-04-09 Document Format Files Seq Description Document Type Size 1 6-K a20260410pixclarandaacce.htm 6-K 13460 2 EX-99.1 telix-6kforpixclararesubmi.htm EX-99.1 21549 3 a20260410pixclarandaacce001.jpg GRAPHIC 284286 4 a20260410pixclarandaacce002.jpg GRAPHIC 218644 5 a20260410pixclarandaacce003.jpg GRAPHIC 196737 Complete submission text file 0001628280-26-024572.txt 999932 Mailing Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 Business Address 55 FLEMINGTON ROAD NORTH MELBOURNE C3 3051 61 3 9093 3855 Telix Pharmaceuticals Ltd (Filer) CIK : 0002007191 (see all company filings) EIN. : 000000000 | State of Incorp.: C3 | Fiscal Year End: 1231 Type: 6-K | Act: 34 | File No.: 001-42128 | Film No.: 26852966 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)